ADA 2017: Insulins go Head-to-Head
Insulin degludec vs glargine--which costs less per anum and why? We summarize this study and 2 other direct insulin comparisons reported at ADA 2017.
American Diabetes Association 77th Scientific Sessions, June 9-13, 2017, San Diego, CA
Studies at the American Diabetes Association (ADA) 77th Scientific Sessions included direct comparisons of a variety of insulin formulations and regimens. Click through the slides above for summaries of 3 studies that evaluate basal insulins in elderly patients; examine the differences between an insulin/oral agent vs insulin only regimen; and report on a cost-benefit analysis of insulin glargine vs insulin degludec -- one costs less because it causes less hypoglycemia.
Recent Videos
Impact of Social Determinants of Health on Key Cardiometabolic Measures Amplified by New Research
Intermediate Cardiometabolic Risk: Study Author Explains this "Critical Inflection Point"
US Cardiometabolic Health at Alarming Suboptimal Levels, Says Lead Author of New NHANES Analysis
Beyond HbA1c: Take a Global Approach to Type 2 Diabetes Management, Use all the Tools
Lessons Learned from the VA on Delay in Second-line Treatment for Type 2 Diabetes
VA Clinical Investigator Discusses HbA1c, Comorbidities as Markers for T2D Treatment Intensification
DiabetesWise Pro: Side-by-side, Feature-by-feature CGM Comparison, Plus More
Kidney Outcomes with Tirzepatide in T2D: Hiddo Heerspink, PhD, PharmD Highlights SURPASS-4 Analysis
A Guide to Prescribing the Right Diabetes Device for your Patients, with DiabetesWise Pro Developer Korey Hood, PhD
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
